Health
Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward – TCTMD
DREAM-HF provides hints of an anti-inflammatory effect and benefits beyond the heart, setting up future trials.
Targeted injection of mesenchymal precursor cells (MPCs) into the myocardium is safe but does not reduce recurrent nonfatal decompensated heart failure (HF) events in patients with chronic HF with reduced ejection fraction (HFrEF), the randomized DREAM-HF…
Continue Reading
-
Business24 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News23 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General18 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General23 hours agoOlder Aussies back increased superannuation tax